EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1

Amy D Shapiro iD, Charles Nakar, Joseph M Parker, Karen Thibaudeau iD, Roberto Crea, Per Morten Sandset iD

Haemophilia · 2023-11 · 29 (6) · 1556-1564

DOI: 10.1111/hae.14849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 06.09.2023. Verfasst von Amy D Shapiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Plasminogen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

An open‐label phase 2/3 study of plasminogen, human‐tvmh administered intravenously in paediatric and adult subjects with type 1 plasminogen deficiency was conducted. Interim data was previously reported. The final data on 15 subjects who completed the study up to a maximum of 124 weeks are reported here.

Methods

The primary objectives were to evaluate efficacy of plasminogen replacement therapy on clinically evident or visible lesions during 48 weeks of dosing and to achieve an increase in trough plasminogen activity levels by at least an absolute 10% above baseline during 12 weeks of treatment.

Results

The primary efficacy endpoint was achieved, as 100% of subjects ( n = 11) with visible and assessable non‐visible lesions at baseline demonstrated ≥ 50% improvement after 48 weeks of study drug treatment with plasminogen, human‐tvmh. All subjects achieved the targeted ≥ 10% increase in trough plasminogen activity above baseline through Week 12. Plasminogen, human‐tvmh at a dose of 6.6 mg/kg administered every 2–5 days for 48 weeks and every 1–7 days for up to 124 weeks was well tolerated.

Conclusion

This study provides additional evidence regarding the long‐term safety and clinical utility of replacement therapy with human plasminogen for the treatment of children and adults with type 1 plasminogen deficiency. Plasminogen, human‐tvmh received marketing approval on June 4, 2021. This trial was registered at www.clinicaltrials.gov as #NCT02690714.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasminogenHumansChildAdultTreatment Outcome

Stichwörter der Autor:innen

NCT02690714human-tvmhhypoplasminogenemiaphase 2/3plasminogenplasminogen deficiency type 1replacement therapy

Substanzen

Plasminogen

Autor:innen und Institutionen

  • Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
  • Prometic Biotherapeutics Inc, Rockville, Maryland, USA.
  • Prometic Bioproduction, Laval, Quebec, Canada.
  • Kedrion S.p.A, Castelvecchio Pascoli, Barga (LU), Italy.
  • Department of Hematology, Oslo University Hospital and University of Oslo, Oslo, Norway.

ORCID-Profile: Amy D Shapiro, Karen Thibaudeau, Per Morten Sandset

Zitieren

APA

Shapiro, A. D., Nakar, C., Parker, J. M., Thibaudeau, K., Crea, R., & Sandset, P. M. (2023). Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia, 29(6), 1556-1564. https://doi.org/10.1111/hae.14849

Vancouver

Shapiro AD, Nakar C, Parker JM, Thibaudeau K, Crea R, Sandset PM. Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia. 2023;29(6):1556-1564. doi:10.1111/hae.14849

BibTeX
@article{Shapiro2023,
  author = {Shapiro, Amy D and Nakar, Charles and Parker, Joseph M and Thibaudeau, Karen and Crea, Roberto and Sandset, Per Morten},
  title = {Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1},
  journal = {Haemophilia},
  year = {2023},
  volume = {29},
  number = {6},
  pages = {1556--1564},
  doi = {10.1111/hae.14849}
}
Kostenlos starten →